Comparing how long people stay on upadacitinib vs TNF inhibitors for RA
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study compares how well people with rheumatoid arthritis stay on two types of medicines: upadacitinib (Rinvoq) and TNF inhibitors. It looks at real-world experiences in Germany to see if one medicine is more likely to be continued over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of moderate to severe active rheumatoid arthritis.
- Your doctor has already decided to start you on either upadacitinib (Rinvoq) or a TNF inhibitor (like adalimumab, etanercept, etc.) before you learn about this study.
- You have not taken upadacitinib before.
- If your doctor is prescribing a TNF inhibitor, you have not taken that specific TNF inhibitor before.
- You are not currently in another clinical trial with an investigational drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the medication upadacitinib (Rinvoq) works similarly for psoriatic arthritis and rheumatoid arthritis. Participants will have ultrasound imaging to track joint inflammation while taking upadacitinib.
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
This study compares two medicines, ustekinumab and upadacitinib, to see which works better for people with Crohn's disease that hasn't improved with other treatments. Both are taken as injections or pills and aim to reduce inflammation and help you feel better.
This study compares two newer oral medications—tofacitinib and upadacitinib—to see which works better and is safer when added to methotrexate for rheumatoid arthritis. Both medicines help calm the immune system's attack on joints.
This trial looks at how two types of rheumatoid arthritis (RA) medications affect patients. It aims to compare anti-TNF drugs with other RA drugs to see if one type is better.
This study looks at how adults with Crohn's disease or ulcerative colitis are doing after taking upadacitinib (Rinvoq) for at least 12 months. It helps doctors understand treatment patterns and outcomes in real-world settings.
Hear when a new Moderate to Severe Rheumatoid Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.